Novo Nordisk facing pressure as study finds $1k drug can be made for $5

Real‑world use, benefits, and risks

• Ozempic/Wegovy are described as extremely popular, driven by social media, celebrity use, and visible rapid weight loss (30–40+ lbs in months).
• Many see big benefits: obesity reduction, potential reductions in addiction-like behaviors (alcohol, gambling), and better metabolic control.
• Side effects discussed include GI issues (diarrhea, possible gastric paralysis), pancreatitis, thyroid cancer concerns, and possible vision loss.
• Commenters stress that obesity itself is deadly, so risk–benefit tradeoffs may still favor use.

Mechanism and long‑term uncertainty

• Drugs are GLP‑1 agonists, affecting insulin response and central nervous system processes controlling appetite and cravings.
• Concerns about long‑term effects: muscle and bone loss, cardiac/pulmonary issues, pancreatic or insulin dysfunction, and incomplete long‑term cancer data.
• Some argue the body’s complex feedback loops mean side effects are inevitable; others suggest this may still be a net positive breakthrough.

Pricing, cost, and patents

• The “$5 to make vs ~$1,000 to sell” is framed as marginal manufacturing cost vs total cost (R&D, failed trials, regulation, overhead).
• Estimates cited: $300M–$2B to bring a drug to market with ~12% success; some say prices must cover many failures.
• Others argue pharma profits and marketing spend are high, so “R&D justification” is overstated.
• Paper’s modeled prices assume 10–50% profit margins; some say such margins might not sustain innovation under current regulation.
• There is broad agreement prices are far lower outside the US; reasons debated (US subsidizing R&D vs rent‑seeking and weak bargaining).

Health system and ethics debates

• Strong debate over whether lifesaving or transformative drugs should be high‑profit products vs publicly funded, low‑price utilities.
• Some want pharma highly profitable to attract talent and innovation; others liken profit from medicine to profiting from weapons.
• Single‑payer and price regulation (e.g., insulin caps) are cited as levers; US insurance middlemen and opaque pricing are heavily criticized.
• Proposals range from full public funding and production of drugs to value‑based pricing and better antitrust/patent enforcement.

Access, scarcity, and practical issues

• Current supply is constrained; richer patients and countries get priority.
• Non‑diabetics often use Ozempic off‑label or instead of Wegovy due to availability, insurance coverage, and pen dosing tricks to stretch expensive pens.
• Some fear that widespread reliance on such drugs could have evolutionary or social consequences; others dismiss this as speculative or “dysgenic” reasoning.